FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says

FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai